USPTO Art Unit 1675 Prosecution Statistics

Art Unit Information

Art Unit: 1675
Group: 1670
Tech Center: 1600
Total Cases: 6,197
Last Active: October 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19364297FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATIONOctober 2025March 2026Allow400YesNo
19251906ANTI-CD79B PROTEIN MONOCLONAL ANTIBODY, PRODUCTS CONTAINING THE SAME, AND USES THEREOFJune 2025September 2025Allow300NoNo
19252441ANTI-TREM2 AGONIST ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF THAT CAN INCREASE LEVELS OF SOLUBLE TREM2 IN SERUM AND BRAIN TISSUEJune 2025November 2025Allow511YesNo
19091464NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHYMarch 2025February 2026Allow1120YesNo
18996523PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOFJanuary 2025February 2026Allow1320NoNo
18984062METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIERDecember 2024September 2025Allow910NoNo
18981054ANTI-HUMAN NR1 ANTIBODY DERIVATIVEDecember 2024March 2025Allow300YesNo
18966342MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO)December 2024January 2026Abandon1410NoNo
18869122QUINONE PROTECTED FORMS AND CONJUGATESNovember 2024February 2026Allow1411YesNo
18955996METHODS OF ADMINISTERING VITAMIN A AND LACTIC ACID TO GILTSNovember 2024June 2025Allow610NoNo
18953476METHODS FOR PREVENTING AND TREATING BRAIN INFLAMMATIONNovember 2024November 2025Allow1130YesNo
18899511METHOD FOR AMELIORATING OR AVOIDING THE ADVERSE EFFECTS OF EXOGENOUS GONADOTROPINS ON REPRODUCTIVE PERFORMANCESeptember 2024April 2025Allow720NoNo
18892253ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING PTK7September 2024May 2025Allow810YesNo
18823422ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOFSeptember 2024January 2025Allow510YesNo
18763515DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSETJuly 2024December 2025Allow1810YesNo
18759577PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFJune 2024October 2025Abandon1611NoNo
18743624GENE THERAPY FOR NEURODEGENERATIVE DISORDERSJune 2024January 2026Abandon1901NoNo
18738824TRANSTHYRETIN ANTIBODIES AND USES THEREOFJune 2024March 2025Allow900YesNo
18735006METHODS AND COMPOSITIONS FOR DIAGNOSING BRAIN INJURY OR NEURODEGENERATIONJune 2024October 2025Allow1710YesNo
18731146HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOFMay 2024January 2025Allow710NoNo
18649453MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOFApril 2024November 2025Allow1910NoNo
18646957GENE THERAPIES FOR LYSOSOMAL DISORDERSApril 2024September 2025Allow1720YesNo
18645977PROTEIN BIOMARKER INDICATORS OF NEUROLOGICAL INJURY AND/OR DISEASE AND METHODS OF USE THEREOFApril 2024January 2026Allow2111YesNo
18640030NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURYApril 2024August 2025Abandon1610NoNo
18637522ANTI-PD-L1 ANTIBODY AND USE THEREOFApril 2024July 2025Allow1510NoNo
18637770BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITIONApril 2024December 2025Allow2010NoNo
18636026TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHApril 2024December 2025Abandon2031NoNo
18635980TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHApril 2024December 2025Abandon2031NoNo
18631672ANTIBODIES BINDING PD-1 AND USES THEREOFApril 2024March 2025Allow1100YesNo
18630179CONJUGATES COMPRISING CLEAVABLE BETA-GLUCURONIDE-CONTAINING LINKERSApril 2024December 2024Allow811NoNo
18627244TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHApril 2024July 2025Abandon1521NoNo
18627162TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHApril 2024July 2025Abandon1621NoNo
18611130TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHMarch 2024July 2025Abandon1621NoNo
18609247TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESMarch 2024September 2024Allow610NoNo
18609223ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESMarch 2024September 2024Allow610NoNo
18607723METHODS OF TREATING PRADER-WILLI SYNDROMEMarch 2024August 2025Abandon1710NoNo
18604668ANTIBODIES TO AMYLOID BETAMarch 2024February 2025Allow1100NoNo
18603613BARCODE DIFFUSION-BASED SPATIAL OMICSMarch 2024May 2024Allow200NoNo
18603889METHOD OF DETERMINING TOXICITY OF AN IMMUNOMODULATORY DRUG FOR USE IN HUMANSMarch 2024August 2025Allow1711YesNo
18600801COMPOSITIONS AND METHODS FOR DISSOLVING PROTEIN AGGREGATESMarch 2024June 2025Allow1520NoNo
18596310ALPHA-SYNUCLEIN DETECTION USING BEADSMarch 2024July 2025Allow1620NoNo
18592478RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION FOR THE TREATMENT OF CORNEAL ENDOTHELIAL DYSFUNCTIONFebruary 2024January 2025Abandon1111YesNo
18588150METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERSFebruary 2024August 2025Abandon1810NoNo
18686041RECOMBINANT PROTEIN OF NERVE GROWTH FACTOR MUTANT AND USE THEREOFFebruary 2024January 2026Abandon2221NoNo
18443769GDNF FUSION POLYPEPTIDES AND METHODS OF USE THEREOFFebruary 2024April 2025Allow1410NoNo
18443416USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A HUMAN SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBIFebruary 2024December 2025Abandon2210NoNo
18442889Human Anti-SOD1 AntibodiesFebruary 2024March 2026Abandon2511NoNo
18441469BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOFFebruary 2024November 2025Allow2110NoNo
18437692TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHFebruary 2024July 2025Abandon1731YesNo
18436678ANTI-APOE ANTIBODIESFebruary 2024September 2025Allow2011YesNo
18435815HUMAN ANTIBODIES TO ARTEMIN AND METHODS OF USE THEREOFFebruary 2024May 2025Allow1510NoNo
18435766METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDESFebruary 2024August 2024Abandon611NoNo
18435809ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOFFebruary 2024March 2025Abandon1401NoNo
18432028Engineered Therapeutic Probiotic System and MethodFebruary 2024January 2026Allow2320YesNo
18430862COMPOSITIONS COMPRISING A T CELL REDIRECTION THERAPEUTIC AND A VLA-4 ADHESION PATHWAY INHIBITORFebruary 2024May 2025Abandon1501NoNo
18430589FUSION IMAGING GENE AND LENTIVIRAL EXPRESSION PLASMID, LENTIVIRUS, CELL, PREPARATION METHODS AND APPLICATIONS THEREOFFebruary 2024August 2024Allow701NoNo
18423089METHODS OF TREATING TUMORSJanuary 2024October 2025Allow2131YesNo
18421058DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERSJanuary 2024January 2026Abandon2441NoNo
18417708MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORSJanuary 2024September 2025Allow2010YesNo
18417630COMPOSITIONS AND METHODS OF MUSCLE SPECIFIC KINASE CHIMERIC AUTOANTIBODY RECEPTOR CELLSJanuary 2024January 2026Allow2420NoNo
18416639SYSTEMS AND METHODS FOR BIOMOLECULE RETENTIONJanuary 2024May 2024Allow411YesNo
18415419HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOFJanuary 2024December 2024Allow1100YesNo
18403043COMPOUNDS AND METHODS FOR TREATING PAINJanuary 2024January 2026Abandon2420NoNo
18402899IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSEJanuary 2024January 2026Abandon2421YesYes
18400744IMMUNE PROFILING BY PRIMER EXTENSION TARGET ENRICHMENTDecember 2023April 2024Allow310NoNo
18395097PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING COX2 ACETYLATING AGENT AS ACTIVE INGREDIENTDecember 2023June 2025Allow1820NoNo
18393420Antibody PurificationDecember 2023September 2025Allow2111NoNo
18540403Methods of Treating a Spastic Disorder in a Subject Having Underlying Condition(s)December 2023February 2025Abandon1421NoNo
18537578METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIADecember 2023June 2025Abandon1801NoNo
18536654METHODS AND KITS FOR LABELING CELLULAR MOLECULESDecember 2023March 2024Allow310NoNo
18533066MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODINGDecember 2023April 2024Allow410YesNo
18531052TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHDecember 2023July 2025Abandon1941YesNo
18531407TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTHDecember 2023November 2025Abandon2351YesNo
18529590METHODS FOR PROMOTING WOUND HEALINGAND HAIR GROWTH COMPRISING GDNF ADMINISTRATIONDecember 2023March 2025Allow1511NoNo
18529720DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHYDecember 2023March 2026Allow2721NoNo
18528535CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASEDecember 2023October 2025Allow2311NoNo
18526952COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED DISEASESDecember 2023June 2025Abandon1901NoNo
18524769SARS-COV-2 ANTIBODIES AND METHODS OF SELECTING AND USING THE SAMENovember 2023April 2025Abandon1601NoNo
18525736NOVEL ANTI-A2AP ANTIBODIES AND USES THEREOFNovember 2023September 2024Allow1011NoNo
18522503METHOD FOR PREVENTING AND/OR TREATING SYSTEMIC INFLAMMATIONNovember 2023March 2026Allow2720NoNo
18521777Methods of Treating an Optic Disease in a SubjectNovember 2023November 2025Abandon2421NoYes
18516397COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1November 2023March 2026Abandon2820NoNo
18513394SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACYNovember 2023July 2025Abandon2001NoNo
18512323METHOD OF SCREENING COMPOUNDS FOR TREATING CNS DISORDERSNovember 2023November 2025Abandon2420NoNo
18509866DETECTION OF PATHOLOGICAL PROTEIN AGGREGATIONNovember 2023October 2025Allow2320YesNo
18507265TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN GNovember 2023August 2025Allow2110NoNo
18506582CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIRNovember 2023July 2025Abandon2101NoNo
18386066METHODS AND SYSTEMS FOR CHARACTERIZING ANALYTES FROM INDIVIDUAL CELLS OR CELL POPULATIONSNovember 2023May 2024Allow611YesNo
18494355IL-2 VARIANTS WITH REDUCED BINDING TO IL-2 RECEPTOR ALPHA AND USES THEREOFOctober 2023August 2024Allow900NoNo
18493744ANTIBODY COCKTAIL AGAINST SARS-COV-2 SPIKE PROTEINOctober 2023July 2025Abandon2010YesNo
18492028ENGINEERED ANTI-IL-2 ANTIBODIESOctober 2023December 2024Allow1300YesNo
18490689METHODS FOR TREATING SYSTEMIC SCLEROSISOctober 2023July 2025Abandon2110NoNo
18489216ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATESOctober 2023December 2024Allow1410NoNo
18486417METHOD OF IDENTIFYING MALODOR MODULATING COMPOUNDSOctober 2023November 2025Abandon2511NoNo
18478846Antibody Molecules to C5AR1 and Uses ThereofSeptember 2023May 2025Allow1911NoNo
18475838COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURYSeptember 2023August 2024Allow1120NoNo
18372072DIMERIZATION SCREENING ASSAYSSeptember 2023April 2024Allow611YesNo
18472920ANTI-TCR ANTIBODY MOLECULES AND USES THEREOFSeptember 2023April 2025Allow1811NoNo
18471948PROFILING OF BIOLOGICAL ANALYTES WITH SPATIALLY BARCODED OLIGONUCLEOTIDE ARRAYSSeptember 2023October 2024Abandon1211NoNo
18370557COMPOSITIONS, DEVICES AND METHODS FOR TREATING AUTISMSeptember 2023December 2025Abandon2611NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1675.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
87
Examiner Affirmed
52
(59.8%)
Examiner Reversed
35
(40.2%)
Reversal Percentile
80.5%
Higher than average

What This Means

With a 40.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
567
Allowed After Appeal Filing
128
(22.6%)
Not Allowed After Appeal Filing
439
(77.4%)
Filing Benefit Percentile
10.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1675 - Prosecution Statistics Summary

Executive Summary

Art Unit 1675 is part of Group 1670 in Technology Center 1600. This art unit has examined 6,197 patent applications in our dataset, with an overall allowance rate of 64.4%. Applications typically reach final disposition in approximately 29 months.

Comparative Analysis

Art Unit 1675's allowance rate of 64.4% places it in the 21% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1675 receive an average of 2.07 office actions before reaching final disposition (in the 65% percentile). The median prosecution time is 29 months (in the 58% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.